Merz Therapeutics Finishes Recruitment for Migraine Trials
The company has completed enrollment of 1,800 participants for two late-stage clinical studies evaluating XEOMIN.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Do you feel new medical treatment options are becoming available fast enough in your country?
Merz Therapeutics has successfully finalized patient recruitment for its MINT-E and MINT-C Phase III clinical trials. These studies are evaluating the efficacy of XEOMIN as a preventative treatment for episodic and chronic migraines in adults.
Why it matters
The completion of these trials marks a significant step in determining whether XEOMIN can offer a new therapeutic option for migraine prevention. Successful results would represent a major expansion for the drug, which is already used for other medical purposes in over 80 countries.
The clinical trials included 1,800 adult participants across 109 study sites in North America and Europe. XEOMIN is currently approved for various medical indications in more than 80 countries, though it is not yet authorized for migraine prevention.
The players
Merz Therapeutics
This organization is a division of the 117-year-old Merz Group headquartered in Frankfurt am Main, Germany.
XEOMIN
This is a therapeutic product currently approved for various indications in over 80 countries.
The details
The MINT-E and MINT-C trials measure the primary endpoint of changes in monthly migraine days at the 6-month mark. Researchers are also tracking secondary endpoints, including frequency of migraines, monthly headache days, and the number of days participants require acute medication.
Timeline
October 15, 2026: Merz Therapeutics announced the completion of patient recruitment.
2027: The main study period is expected to conclude.
The Big Picture
The MINT-E and MINT-C Phase III clinical trials represent a focused effort to expand the application of existing neurotoxin-based therapies into the highly prevalent field of migraine management.
While XEOMIN is currently not approved for migraine prevention, these trials provide insight into potential future treatment options for patients. If approved, this could introduce a new preventative therapy to a market impacting 1.1 billion people worldwide.
The takeaway
Patients suffering from migraines should monitor the results of these trials for potential shifts in the standard of care. Consult with a healthcare provider regarding current FDA-approved treatment options for migraine prevention while awaiting further study data.
Further reading
For additional context on neurological health research, visit the Alzheimer’s section.
Live Poll
Do you feel new medical treatment options are becoming available fast enough in your country?
